Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani: We Developed a Comprehensive Health System so as not to Exclude any Citizen from the Universal Coverage

 
NNA- The administration and justice committee held a meeting presided by Deputy Robert Ghanem in the presence of Deputy Prime Minister Health Minister Ghassan Hasbani and deputies: Hani Kobaisy, Elie Aoun, Serge Torsarkisian, Atef Majdalani, Ghassan Moukhayber, Nawaf Mousawi, the representatives of Health Ministry Fadi Mosallem and the Ministry of Social Affairs Adnan Naser Eddine, Director General of the National Social Security Fund Dr. Muhammad Karaki, Head of NSSF Diwan Chawki Abou Nassif, the representative of the Ministry of Finance Nahla Boustani, the President of the General Confederation of Lebanese Workers Bechara Asmar.

Ghanem

“This is the eighth meeting of the administration and justice committee to study the so-called visa coverage card; the mandatory universal healthcare coverage suggested by Dr Atef Majdalani and studied by the Health committee. When H.E. Hasbani became Health Minister, he asked that this subject be more comprehensive. A study was conducted to include the majority of the Lebanese citizens,” stated the committee’s president.

Hasbani

“I would like to thank and congratulate the administration and justice committee for discussing the proposal of the law submitted by Deputy Atef Majdalani. The Ministry of Public Health made observations based on a recent study this year on the health coverage or the mandatory universal health care. The detailed study with experts includes many observations made on this subject to develop the system so as not to exclude any citizen from the universal coverage; primary health care, inpatient and outpatient services,” outlined Hasbani.

Majdalani

“I would like to thank my colleague Mr. Robert Ghanem, the president of the administration and justice committee for his help and seriousness in scheduling the meetings of the committee and contribution in the discussions. I thank as well Health Minister Ghassan Hasbani for the amendments of Health Ministry to expand the network of social and health solidarity in the proposal of the law we suggested in 2013,” said Majdalani.
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
R05CB01 ACC LONG G N-acetylcysteine - 600mg, Vitamin C - 75mg 600mg Tablet, effervescent 286,238 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 400mg 400mg Tablet, coated 615,480 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 200mg 200mg Tablet, coated 464,970 L.L
M01AB16 ACECLOFAR G Aceclofenac - 100mg 100mg Tablet 131,697 L.L
S01EC01 ACETAZOLAMIDE G Acetazolamide - 250mg 250mg Tablet 1,001,163 L.L
B03BB01 ACFOL G Folic acid - 5mg 5mg Tablet 355,798 L.L
M02AA10 ACHONID GEL G Ketoprofen - 2.5% 2.5% Gel 179,179 L.L
M05BB03 ACIDE ALENDRONIQUE/ VITAMINE D3 BGR G Alendronic acid - 70mg, Colecalciferol - 5600UI Tablet 815,712 L.L
D06AX01 ACIDE FUSIDIQUE BGR G Fusidic acid - 2% 2% Cream 202,920 L.L
M05BA08 ACLASTA B Zoledronic acid (monohydrate) - 5mg/100ml 5mg/100ml Injectable solution 21,075,062 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 80mg/4ml 80mg/4ml Injectable concentrated solution 11,127,864 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 162mg/0.9ml 162mg/0.9ml Injectable solution 79,959,812 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 200mg/10ml 200mg/10ml Injectable concentrated solution 25,485,937 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 400mg/20ml 400mg/20ml Injectable concentrated solution 47,925,322 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 80mg/4ml 80mg/4ml Injectable concentrated solution L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 162mg/0.9ml 162mg/0.9ml Injectable solution L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 200mg/10ml 200mg/10ml Injectable concentrated solution L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 400mg/20ml 400mg/20ml Injectable concentrated solution L.L
J05AB01 ACTI-VIR G Aciclovir - 200mg 200mg Tablet, scored 1,039,238 L.L
D06BB53 ACTI-VIR H G Aciclovir - 5%, Hydrocortisone acetate - 1% Cream 833,182 L.L
A03E ACTICARBINE G Activated charcoal - 70mg, Papaverine HCl - 14mg Tablet, coated 306,396 L.L
B01AD02 ACTILYSE BioTech Alteplase - 50mg 50mg Injectable dry powder for solution+diluent 100,976,553 L.L
N02AA01 ACTISKENAN G Morphine sulfate - 30mg 30mg Capsule, immediate release 763,303 L.L
N02AA01 ACTISKENAN G Morphine sulfate - 20mg 20mg Capsule, immediate release 512,004 L.L
N02AA01 ACTISKENAN G Morphine sulfate - 10mg 10mg Capsule, immediate release 310,428 L.L
N02AA01 ACTISKENAN G Morphine sulfate - 5mg 5mg Capsule, immediate release 233,829 L.L
R05X ACTISOUFRE B Sulfure de Sodium - 13mg, Saccharomyces Cerevisiae - 500mg Solution 729,706 L.L
A02AF02 ACTONORM B Aluminium hydroxide - 220mg/5ml, Magnesium hydroxide - 200mg/5ml, Simethicone - 25mg/5ml Suspension 403,153 L.L
A10BG03 ACTOS B Pioglitazone HCl - 30mg 30mg Tablet 2,484,765 L.L
A10BG03 ACTOS B Pioglitazone HCl - 15mg 15mg Tablet 1,243,054 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026